Sagent Pharmaceuticals has announced the temporary importation of 8.4% Sodium Bicarbonate Injection, USP into the US market from Australia-based Phebra.
The temporary arrangement is to address the present critical shortage of non-FDA approved Sodium Bicarbonate Injection, USP in the region.
Sagent president, chief executive officer and board chairman Jeffrey Yordon said at present sodium bicarbonate is on the drug shortage lists of both the FDA and American Society of Health-System Pharmacists.
"We are pleased to provide a temporary source of this critical product to help address the current shortage, and we continue to advance long-term solutions to the overall drug shortage situation," Yordon added.
Sodium Bicarbonate Injection is an electrolyte replenisher and systemic alkalizer indicated for the treatment of metabolic acidosis and certain drug intoxications.
Metabolic acidosis usually occurs in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis.
